Skip to Main Content
Table 1.

Incidence of HER2-activating mutations by histology, hormone receptor status, and tumor tissue source for patients whose tumor samples successfully sequenced at GPS laboratory

Positive for HER2 mutation, N (%)P
Histology 
 Invasive ductal carcinoma (n = 309) 5 (1.6%) 0.026a 
 Invasive lobular carcinoma (n = 51) 4 (7.8%)  
 Invasive ductal/lobular carcinoma (n = 12) 0 (0%)  
 Otherb (n = 9) 0 (0%)  
Hormone receptor status 
 ER+ and/or PR+ (n = 277) 9 (3.2%) 0.219 
 ER PR HER2 (n = 82) 0 (0%)  
 Unknown (n = 17) 0 (0%)  
Samples tested 
 Primary breast cancer (n = 256) 6 (2.3%) >0.99 
 Metastatic site (n = 125) 3 (2.4%)  
Total (n = 381)  
Positive for HER2 mutation, N (%)P
Histology 
 Invasive ductal carcinoma (n = 309) 5 (1.6%) 0.026a 
 Invasive lobular carcinoma (n = 51) 4 (7.8%)  
 Invasive ductal/lobular carcinoma (n = 12) 0 (0%)  
 Otherb (n = 9) 0 (0%)  
Hormone receptor status 
 ER+ and/or PR+ (n = 277) 9 (3.2%) 0.219 
 ER PR HER2 (n = 82) 0 (0%)  
 Unknown (n = 17) 0 (0%)  
Samples tested 
 Primary breast cancer (n = 256) 6 (2.3%) >0.99 
 Metastatic site (n = 125) 3 (2.4%)  
Total (n = 381)  

aComparison between ductal carcinoma (n = 309) vs. lobular carcinoma (n = 51).

bOthers include metaplastic (n = 2); mucinous (n = 3); and unknown (n = 4).

Close Modal

or Create an Account

Close Modal
Close Modal